Product Details
| Product Name:
Zunsemetinib |
CAS No.:
1640282-42-3 |
| Purity:
99.77% |
Supply Ability:
10g |
| Release date:
2025/11/10 |
Product Introduction
Bioactivity
| Name | Zunsemetinib |
| Description | Zunsemetinib (ATI-450) is an orally active and selective inhibitor of the p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway.Zunsemetinib is used to study spondyloarthritis and rheumatoid arthritis. |
| In vitro | Zunsemetinib selectively blocks p38α MAPK activation of the proinflammatory kinase MK2 while sparing p38α activation of other effectors such as PRAK and ATF2, and inhibits in vitro osteoclast formation induced by RANKL.[1]
Zunsemetinib (1 and 10 μM; 1h) decreases IL-1β expression by promoting IL-1β mRNA degradation and has no effect on NLRP3 expression.[1]
Zunsemetinib (0.4 nM~1 μM; 16h; PBMC cells) reduces IL-1β secretion and promotes IL-1β mRNA instability.[1] |
| In vivo | Zunsemetinib (1,000 ppm; p.o.; 8-week-old WT female mice) blocks LPS-induced TNF-α expression persisted for up to 4 weeks after dosing.[1]
Zunsemetinib (10 and 20 mg/kg; p.o.) prevents osteopenia in NOM IDc mice through inhibition of osteoclastogenesis and increases bone density.[1] |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 80 mg/mL (155.67 mM), Sonication is recommended.
|
| Keywords | Zunsemetinib | MK2 | CDD450 | CDD 450 | ATI450 | ATI 450 |
| Inhibitors Related | Sodium lauryl sulfoacetate | Nomilin | CMPD1 | Vemurafenib | SKLB-163 | MBM-55S | sodium lauroyl-α-hydroxyethyl sulfonate | RV01 | Takinib | NG25 | MK2-IN-3 hydrate | Selonsertib |
| Related Compound Libraries | Reprogramming Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Breast Cancer Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | MAPK Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:68377-91-3
$48.00 / 1mg
-
CAS:2361659-61-0
$76.00 / 1mg
-
CAS:174254-13-8
$518.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States